Rani Q3 Loss Widens to $8.8M; $45.3M Cash Funds Operations Through 2027
RANI is trading near its 52-week low of $0.51 (7.9% above the low).
Summary
Rani reported a Q3 2026 net loss of $8.8 million and held $45.3 million in cash and securities, enough to fund operations at least through the end of 2027; the company also disclosed FDA acceptance into its Emerging Technology Program.
Key Events · Earnings and Guidance · RANI
-
Q3 Loss Widens on Higher R&D
Net loss was $8.8 million versus $7.9 million a year earlier, as R&D rose to $6.0 million from $3.2 million.
-
Cash Runway Extended to End-2027
Cash, equivalents and marketable securities totaled $45.3 million at September 30, 2026, down from $53.4 million at June 30, 2026, but sufficient to fund operations at least through the end of 2027.
-
First Chugai Contract Revenue Booked
Contract revenue of $1.7 million in Q3 2026 versus none a year earlier, primarily from the Chugai collaboration and license agreement.
-
FDA Emerging Technology Program Acceptance
In October 2026 the RaniPill Capsule platform was accepted into the FDA's Emerging Technology Program, enabling early engagement on technical, manufacturing and regulatory issues; it is not an approval.
Analysis · RANI · Life Sciences
For a clinical-stage company burning cash, two items in this quarterly update stand out: runway was extended to at least the end of 2027 on $45.3 million of cash and securities, and the FDA accepted the RaniPill platform into its Emerging Technology Program. The trade-off is a wider loss — $8.8 million versus $7.9 million a year ago — as R&D spending jumped to $6.0 million from $3.2 million, partly offset by the first $1.7 million of Chugai contract revenue. Against a prior 10-Q that already disclosed a Nasdaq delisting notice and a material weakness in internal controls, the runway extension is the key survival data point; the next hard catalyst is the additional RT-114 Phase 1a data expected by the end of 2026.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RANI was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.1M. The 52-week trading range was $0.51 to $2.16. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.